InnoCare’s New Lymphoma Treatment Enters Priority Review

InnoCare Pharma Ltd. (HK:9969) has released an update.

InnoCare Pharma Ltd. has announced that China’s National Medical Products Administration has accepted and given priority review to their Biologics License Application for tafasitamab in combination with lenalidomide, aimed at treating adults with relapsed or refractory Diffuse Large B-cell Lymphoma who aren’t eligible for stem cell transplant. The application is backed by positive phase II study results, which have already led to tafasitamab’s approval in Hong Kong and under early access in select medical zones. Moreover, Incyte has secured global rights to develop and commercialize tafasitamab in a recent agreement.

For further insights into HK:9969 stock, check out TipRanks’ Stock Analysis page.